- Trial phase
- Approved
- Time to market
- Already approved and marketed since January 2021.
- Why 3/10
- VERQUVO is already approved and marketed with no pending regulatory decision or pivotal readout scheduled in the next ~12 months. The last major catalyst (VICTOR trial readout, August 2025) has passed. The drug is a very small contributor to Merck's $65B+ annual revenue, so even a major commercial event would have minimal impact on MRK's share price.
VERQUVO has no upcoming binary catalyst. The VICTOR trial failure in August 2025 was the last major event. For Merck investors, the drug is a negligible revenue contributor and not a meaningful swing factor for the stock. Watch for any FDA action on a potential label expansion based on the VICTOR/VICTORIA pooled analysis, but no such filing has been announced. Merck's Q3 2026 earnings released today (Oct 29, 2026) showed total sales of $18.09 billion, with Verquvo buried within the 'Other' or alliance revenue line.
Price Chart
Executive Summary
VERQUVO (vericiguat) is an FDA-approved heart failure drug from Merck & Co. (MRK) and co-developer Bayer. It was approved in January 2021 to reduce cardiovascular death and hospitalization risk in patients with worsening chronic heart failure with reduced ejection fraction. The drug has a novel mechanism as an sGC stimulator but has struggled commercially, generating only about $21 million in U.S. sales in the first half of 2025. A Phase 3 trial (VICTOR) in stable patients without recent worsening failed its primary endpoint in August 2025, though a pooled analysis showed broader benefit. VERQUVO is a very small part of Merck's diversified $65B+ revenue base, competing against much larger therapies like Novartis' Entresto and SGLT2 inhibitors.
How It Works
VERQUVO is a soluble guanylate cyclase (sGC) stimulator. It works by helping blood vessels relax and widen, which reduces the workload on the heart. It is taken as a once-daily oral tablet.
Trial Status
VERQUVO was approved by the FDA in January 2021 based on the positive Phase 3 VICTORIA trial in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF). A subsequent Phase 3 trial (VICTOR), read out in August 2025, tested VERQUVO in stable HFrEF patients without a recent worsening event. VICTOR failed its primary composite endpoint (cardiovascular death or heart failure hospitalization), though a pooled analysis with VICTORIA showed a significant benefit across the broader HFrEF population. The drug carries an FDA label for use after a recent hospitalization or need for IV diuretics.
The Two-Sided Case
Upcoming Catalysts
- No major binary catalyst is scheduled. The drug is already approved and commercializing. Future catalysts would be limited to potential label expansion data or guideline updates.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report